Please login to the form below

Not currently logged in
Email:
Password:

Ex-GSK CEO Jean-Pierre Garnier takes up role at Alzheon

He will be the US biopharma's chairman of board of directors

Alzheon Jean-Pierre GarnierFormer GlaxoSmithKline chief executive Jean-Pierre Garnier has been appointed chairman of board of directors at US-based clinical-stage biopharmaceutical company Alzheon.

The firm focuses on brain health, memory and ageing and its lead product is an oral amyloid aggregation inhibitor that targets Alzheimer's disease.

Alzheon's founder, president and chief executive officer Martin Tolar said: “JP will provide invaluable insights and guidance as we advance our lead oral amyloid aggregation inhibitor, ALZ-801, into a phase III clinical programme targeting a genetically-defined Alzheimer's disease population, and execute on our long-term strategy to bring innovative therapies to patients with neurodegenerative disorders.”

Garnier served as SmithKline Beecham's chief executive officer, having joined the company in 1990 as president of pharmaceuticals for North America.

He subsequently became GSK's first CEO following its formation from the merger of Glaxo Wellcome and SmithKline Beecham in 2001 and he held that position until in 2008.

Garnier then became chief executive officer of Pierre Fabre Laboratories and chairman of biotechnology company Cerenis.

He is currently chairman of the board of directors for Swiss biopharmaceutical company Actelion.

11th December 2015

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
90TEN

90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...

Latest intelligence

Patient engagement
Taking a holistic approach to patient care
The importance of recognising each patient as an individual...
The concordance conundrum – the tech divide
“Hello? Can you hear me? I think you are on mute” – how many times have we all heard this over the past five or so months? Not exactly the...
3 ways to increase patient retention rates in clinical trials
Retention rates are falling in clinical trials. Yes, it is a bit disheartening. But there are some straightforward things you can do to turn it around....

Infographics